Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this prospective phase II observational study, we plan to assess the efficacy and tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in a group of patients received allo-HSCT transplantation with high risk of IFI: HLA matched unrelated donor or mismatched donor conditioning with ATG containing regimen or present III-IV aGVHD or extensive GVHD undergoing high-dose steroid treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Liposomal amphotericin B; Miconazole; Voriconazole

Criteria

Inclusion Criteria:

• adult patient undergoing allogeneic hematopoietic stem cell transplantation

• age 18-55 years

• with inform consent

• no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage

• HLA mismatched related (3~5/6) or unrelated donors (at least 8/10)

• proven or probable IFI

Exclusion Criteria:

• age less than 18 years or over 56 years

• HLA mismatched related donor

• liver function/renal function damage (over 2 X upper normal range)

• with mental disease